KR20090127854A - Skin compositions for exteral application, containing plant extracts - Google Patents

Abstract

PURPOSE: A skin external composition containing medicinal herb extract is provided to suppress proliferation of interleukin-2 and -4 and T lymphocyte and treat or prevent dermatitis such as atopic dermatitis, contact dermatitis and psoriasis. CONSTITUTION: A skin external composition for treating or preventing atopic dermatitis, contact dermatitis or psoriasis contains Bistorta manshuriensis extract as an active ingredient in 0.001~10 weight% based on total weight. A method for preparing Bistorta manshuriensis extract comprises: a step of pulverizing Bistorta manshuriensis and pulverizing a step of adding 95% of ethanol and heating at 80°C for two hours; a step of placing the extract at room temperature for one hour and filtering; and a step of evaporating and concentrating.

Description

Skin composition for external use containing herbal extracts {Skin compositions for exteral application, containing plant extracts}

The present invention relates to a composition for external application for skin containing herbal extracts, and more particularly, to a skin external preparation composition such as Asiasari Radix , Perillae Herba , Perillae Semen , Cimicifugae Rhizoma , Ritual Melandrii Herba , Solani Nigri Herba , Arctii Semen , Potentillae Radix , Broiler ( Cinnamomi Cortex Spissus ), Hoelen rubra , Phaseoli angularis Semen , Excess ( Ammomi Tsao-ko Frucuts ) Hemisphere ( Alpiniae Katsumadaii Semen ), Buckwheat ( Fagopyrum esculentum ), Ming ( Chenopodium album var. Centrorubrum ), Bistorta ( Bistorta manshuriensis ), Lycoris squamigera , Thymus quinquecostatus var. Japonica , Mugwort argunensis And it relates to a composition for external application for skin containing as an active ingredient extract of at least one herbal medicine selected from Pimpinella brachycarpa . The topical skin composition of the present invention aims to improve various skin diseases caused by T lymphocyte mediated immune response, specifically atopic dermatitis, contact dermatitis and psoriasis, and to treat and prevent these skin diseases. Can be used.

Atopic Dermatitis is a complex of skin that is characterized by a combination of symptoms such as strong pruritus, dryness, severe keratinization, torn head, dandruff, erythema and swelling, skin cracks, severe rashes, eczema, and thyroiditis. It is an abnormal syndrome. In many cases, it is a chronic disease that lasts for more than 10 years and causes great inconvenience in long-term life. In the past, infants and infants started in the early stages of growth and the condition was gradually improved and disappeared before the age of 7-8 years. However, since the 1970s, the incidence rate has increased year by year due to the pollution and environmental pollution caused by the rapid industrialization, and the symptoms continue to adolescence and adulthood, and become more severe or newly developed after adolescence. Symptoms are accompanied by strong itching and skin irritation, and excessive secretion of histamine is a major cause of itching. When the skin is scratched due to itching, erythema or eczema appears, and in severe cases, the skin may be peeled off or the lichen may become thickened.

Many studies and information on the cause of atopic dermatitis have been presented until recently, but the exact pathology and effective treatment have not yet been established due to the complexity of the disease itself and conflicting research data. Due to these problems, the atopic dermatitis treatments that have been developed to date help to control symptoms to an appropriate level rather than the fundamental treatment such as steroid preparations, oral antihistamines, hydroxyquinoline, tar preparations, and hypoallergenic moisturizers. Products dominate. However, none of the drugs developed to date fully meet the needs of patients. Until recently, topical steroid preparations have been the main dominant agents for treating atopic dermatitis, but there is an urgent need for development of safer nonsteroidal atopic dermatitis treatments without side effects due to resistance expression and safety problems during long-term use.

Recently, it has been found that abnormally activated immune responses, such as hyperactivity of T lymphocytes and hypersensitivity of IgE, are one of the main causes of atopic dermatitis, contact dermatitis, and psoriasis disease. Attempts to treat these skin diseases by suppressing the response have attracted attention. There are many types of cytokines that control T cell mediated immune responses, but interleukin-2 and interleukin-4 play important roles in the pathology of atopic dermatitis.

Interleukin-2 is a cytokine produced in the early stages of T cell activation and strongly triggering an immune response by stimulating Th cells. In addition, interleukin-4, which has recently been of great interest in the pathogenesis of atopic dermatitis, has been shown to induce a disproportionate activation of Th2 cells, a characteristic pathology of Atopic dermatitis, in particular. At the same time, interleukin-4 is a key cytokine that stimulates B cells to increase IgE production, thereby promoting histamine secretion by mast cells, leading to atopic reactions such as erythema, redness, and itching.

As such, there are known documents describing the fact that immune responses, such as hyperactivity of T lymphocytes and hypersensitivity from IgE, are associated with atopic dermatitis, contact dermatitis, and psoriasis disease. [Leung D and Bieber T. Atopic Dermatitis. Lancet 2003, 361: 151-160, Galli E, Cicconi R, Rossi P, Casati A, Brunetti E, and Mancino G. Atopic Dermatitis: Molecular Mechanisms, Clinical Aspects and New Therapeutical Approaches. Current Molecular Medicine 2003, 3: 127-138, Christophers E. Psoriasis-epidemiology and clinical spectrum. Clinnical Experimental Dermatology 2001, 26 (4): 314-320].

Thus, substances capable of simultaneously inhibiting the production of interleukin-2 and interleukin-4 and the final proliferation of T cells, the end result of these cytokine reactions, may provide better efficacy for the treatment of atopic dermatitis than common immunosuppressive agents. It can be seen that.

Therefore, the inventors of the present invention, while searching for a way to control the abnormally activated immune response in the skin, Seshin, lobules, stool, horse riding, pandemic, Yonggyu, allies, Ulleungchae, broiler, Red Bokyeongryeong, Red Soybeans, Excess, Seconds Extracts of head, buckwheat, tusks, pan-tails, lycopene, thyme, wormwood, and sprouts are interleukin, the key cytokine of T lymphocyte-mediated immune response, and T lymphocyte cytokine, interleukin that stimulates IgE production The present invention was found to have the effect of inhibiting the production of interleukin-4 and excessive proliferation of T lymphocytes.

Therefore, an object of the present invention, by containing at least one of the herbal extracts as an active ingredient, to suppress abnormally activated T lymphocyte-mediated immune response to improve the symptoms of atopic dermatitis, contact dermatitis and psoriasis It is to provide a safe and effective external preparation composition for skin.

In order to achieve the above object, the composition for external application for skin according to the present invention is a thin body, lobules, urea, horse riding, pandemic, yonggyu, allies, ulleungchae, broiler, red bok ryok, red soybeans, excess, chodugu, buckwheat, roe wine, pan-tail It is characterized by containing at least one herb extract selected from among similarity, thyme, wormwood and wormwood as an active ingredient.

Seshin, lobules, urea, horse riding, royal fire, yonggyu, allies, Ulleungchae, broiler, red ox, red soybeans, excess, chodugu, buckwheat, ming zhu, pan-tail, sanghwa, thyme, mugwort, and real greens according to the present invention Compositions containing one or more extracts of herbal medicines inhibit the production of interleukin-2 and interleukin-4, inhibit the proliferation of T lymphocytes, and exhibit specific toxicity to mouse spleen lymphocytes, keratinocytes and fibroblasts. Did. Therefore, the composition according to the present invention was very safe and effectively suppressed T lymphocyte mediated immune response. Therefore, it can be used as a composition capable of treating or preventing atopic dermatitis, contact dermatitis and psoriasis, which are skin diseases related to excessive T lymphocyte mediated immune responses.

In the external preparation composition for skin according to the present invention, the herbal extract is characterized in that it is contained in an amount of 0.001 to 10% by weight, preferably 0.01 to 5% by weight in the total composition.

The topical skin composition of the present invention aims to improve various skin diseases caused by T lymphocyte mediated immune response, specifically atopic dermatitis, contact dermatitis and psoriasis, and to treat and prevent these skin diseases. Can be used. To this end, the external preparation composition for skin of the present invention may be provided as a pharmaceutical composition for the purpose of treating and preventing the skin disease, and may also be provided as a functional cosmetic composition for the purpose of improving the symptoms of the skin disease.

Hereinafter, the present invention will be described in more detail.

The herbal extracts used in the external preparation composition for skin of the present invention, as will be described in detail below, are herbal medicines that have been used for the purpose of improving and treating symptoms of various diseases since ancient times, and have been proven herbal medicines for human safety.

Sesins ( Asiasari Radix ) used in the present invention is a rooted outpost of the perennial herbaceous Asarum heterotropoides var. Mandshuricum belonging to the Aristolochiaceae , it is used for antipyretic calming, analgesic, antitussive action, etc. .

Perillae Herba is a leaf of perennial herb, Perilla frutescens var. Acuta , belonging to Labiatae . It is used for the treatment of asthma, bloating and cold due to sweating and detoxification.

Perillae Semen is a fruit of perilla frutescens var. Acuta, an annual herb, belonging to Labiatae , and is used for the purpose of treating expectorant and constipation.

Horseback riding ( Cimicifugae Rhizoma ) is a root of perennial herb, Cimicifuga foetida or horse riding ( Cimicifuga heracleifolia ), which belongs to Ranunculaceae . .

Melandrii Herba is a seed of Melandrium firmum and Melandrium apricum , a biennial herb belonging to the Caryophyllaceae family. Used for the treatment of bleeding, etc.

Solani Nigri Herba is an outpost of Solanum nigrum , an annual herb belonging to the Solanaceae family .

Arctii Semen is the fruit of Arctium lappa , a biennial herb, which belongs to Compositae , and has antibacterial, hypoglycemic, customary removal, seedling, and detoxification effects.

Potentillae Radix is a root of the perennial herbaceous Potentilla chinensis or Potentilla chinensis var. Concolor, a member of the Rosaceae family . It is used for the treatment of joint pain and skin disease.

The broiler ( Cinnamomi Cortex Spissus ) is a stem and branch bark of an evergreen tree, Cinnamomum loureirii or Cinnamomum cassia , which belongs to the Lauraceae family.

Hoelen rubra is a light red part of the fungal nucleus of Poria cocos belonging to the Polyporaceae family, and is used for the purpose of diuresis, moist heat removal, and the like.

Red bean ( Phaseoli angularis Semen ) is a seed of annual herb, Phaseolus calcaratus or red beans ( Phaseolus angularis ), belonging to Leguminosae , and it is effective for diuresis, wetness, blood loss, drainage and detoxification. It is used to treat symptoms such as jaundice and hari.

Ammomi Tsao-ko Frucuts is a fruit of the perennial herb, Amomum tsao-ko , belonging to the Zingiberaceae family. It is used to treat it.

Alpiniae Katsumadaii Semen is a seed of the perennial herb, Alpinia katsumadai , belonging to the Zingiberaceae family. It is used to treat the symptoms.

Buckwheat ( Fagopyrum esculentum ) is an annual herb of Polygonaceae . Seeds are used for symptoms such as acute enteritis, chronic lower limbs, and round bottom. Stems and leaves are effective for hemostasis and capillary strengthening.

Chenopodium album var.centrorubrum is an annual herb of the Chenopodiaceae and is used for edible, medicinal or feed purposes. It is used for branch, health, and tonic because it has the effect of clearing, dampening, and insecticide.

Bistorta manshuriensis is a perennial herb of the Polygonaceae family, and roots have the effect of clearing , dysmenorrhea , and diarrhea .

Lycoris squamigera is a perennial herb belonging to the family Amaryllidaceae , which has the effects of expectoration, diuresis, detoxification, and top soil.

Thymus quinquecostatus var. Japonica is a perennial herb of Labiatae , whose outpost is used as a respiratory protective agent for bronchitis and as a painkiller for neuritis.

Senecio argunensis is a perennial herb of Compositae , which is used for the treatment of dysentery, acute conjunctivitis, sore throat, eczema, dermatitis, etc., with the outpost having clearing and detoxifying effects.

Pimpinella brachycarpa is a perennial herb of the umbelliferae and uses edible or medicinal outposts. It is used for the purpose of hypertension, prevention of stroke, neurosis, hyperhidrosis, and hemostasis and fever.

The herbal extract used as an active ingredient in the external preparation composition for skin of the present invention has been shown to be effective for improving and treating the symptoms of various diseases as described above, but the inhibitory effect on T lymphocyte-mediated immune responses desired in the present invention. Is not known at all, and it is stated that this is only disclosed by the present invention. In particular, it is not known that the herbal extracts have the effect of inhibiting the production of interleukin-2 and interleukin-4 and excessive proliferation of T lymphocytes, which are the main causes of atopic dermatitis, contact dermatitis and psoriasis.

The amount of the extract used in the present invention is 0.001 to 10% by weight, preferably 0.01 to 5% by weight based on the total weight of the composition based on an in vitro experiment. If the extract content is less than 0.001% by weight, it is difficult to expect to act as an active ingredient, and if the extract content is more than 10% by weight, problems with formulation stability may occur. From this point of view, more preferably used in an amount of 0.01 to 5% by weight.

The external preparation composition for skin according to the present invention can be used for the purpose of improving the symptoms of the skin diseases such as atopic dermatitis, contact dermatitis or psoriasis, further treatment and prevention, and the formulation is not particularly limited. Do not. The external preparation composition for skin of the present invention may be provided as a functional cosmetic composition for the purpose of improving the symptoms of the aforementioned skin diseases, and may also be provided as a pharmaceutical composition for the purpose of treating and preventing the skin diseases.

When the present invention is provided as a functional cosmetic composition, for example, in a soft cosmetics, nourishing cosmetics, massage creams, nutrition creams, packs, gels, essences or formulations of skin adhesive type cosmetics, or lotions, ointments, gels, creams, It may be formulated into a transdermal dosage form such as a patch or spray.

In addition, when the present invention is provided in a pharmaceutical composition, the herbal extract may be used as it is or in the form of a pharmaceutically acceptable salt. The salt is not particularly limited as long as it is pharmaceutically acceptable, and for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid, acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid , Acid addition salts formed by benzenesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid and the like can be used. In addition to acid addition salts, base addition salts such as sodium hydroxide, potassium hydroxide, triethylamine, tert-butylamine can also be used.

The pharmaceutical composition according to the present invention can be formulated by adding various auxiliaries used in medicine, such as carriers or other additives such as stabilizers, emollients, emulsifiers and the like, as long as they do not adversely affect the active ingredient.

In the pharmaceutical composition according to the present invention, the content of the herbal extracts described above may vary widely depending on the formulation and is in accordance with conventional methods.

Pharmaceutical compositions according to the invention may be administered parenterally, transdermal administration is preferred, in particular topical application is most preferred. It may be formulated in a conventional manner using solid or liquid excipients or diluents suitable for topical application. For example, it may be any suitable formulation such as ointment, cream, injection, powder, granules, tablets and the like.

The dosage of the pharmaceutical composition according to the present invention varies depending on the age, condition, and degree of disease of the patient, but preferably 0.001 to 1000 mg / kg · day.

The pharmaceutical compositions according to the invention can be administered alone or in combination with other agents or together to assist other agents.

In addition, in the external preparation composition of each formulation, other components other than the above-mentioned essential components can be suitably selected and blended by those skilled in the art according to the formulation of the external preparation or the purpose of use.

Hereinafter, the configuration and effect of the present invention will be described in more detail with reference to Examples and Test Examples. However, the present invention is not limited only to these examples.

Example 1 Preparation of Herbal Medicine Extract

Sesin, lobules, element, horseback riding, royal trend, dragon gyu, mate, Yureungchae, broiler, red bokyeongryeong, red soybean, excess, chodugu, buckwheat, mingled wine, pan-tail, sanghwa, island thyme, mugwort, and green sprout each 1 kg After adding 95% ethanol in a weight (kg) ratio of 4 times and then heated at 80 ℃ for 2 hours to extract the active ingredient. This was allowed to stand at room temperature for 1 day to precipitate impurities, and the filtrate was filtered twice using a filter paper and concentrated by completely evaporating using a reduced pressure evaporator.

Experimental Example 1 Inhibitory Effect of Interleukin-2 Production

Concanavalin A, a mitogen that reacts by stimulating T lymphocytes to splenocytes of BALB / C mice, was added, followed by treatment of the extracts prepared in Example 1, respectively. The production inhibitory effect was measured.

Specifically, the mouse's spleen cells were placed in a 96-well microtiter plate containing RPMI medium containing 10% fetal bovine serum to 200,000 cells / well, and 2 μg / concavaline A was added. A ml concentration was added to activate T lymphocytes. Each composition was then treated according to the concentration of Table 1 below, and after 24 hours, the interleukin-2 released into the culture was quantified by ELISA (Enzyme-Linked Immunosorbent Assay) method. At this time, using only the concanavalin A and not treated with the composition as a control group to calculate the interleukin-2 production inhibition rate according to Equation 1 shown in Table 1 below.

Inhibition rate (%) = 100 × (control-composition treatment group) / control

Composition density(%) Interleukin-2 production inhibition rate (%) Sesin 0.001 23 Leaflets 0.001 48 device 0.001 63 riding 0.001 43 Bad news 0.001 26 Yonggyu 0.001 33 Allies 0.001 11 Ulleungchae 0.001 27 Broiler 0.001 32 Red flag 0.001 41 Small cow 0.001 43 Excess 0.001 25 Headlights 0.001 93 buckwheat 0.001 21 pigweed 0.001 58 common bistort 0.001 27 Similarity 0.001 50 Island Thyme 0.001 73 Mugwort 0.001 72 Green sprouts 0.001 26 Control - 0

As shown in Table 1, the herbal extract of the present invention was found to have the effect of inhibiting the production of interleukin-2 by activated T lymphocytes at low concentrations of 0.001%, respectively.

Test Example 2 Effect of Inhibiting Interleukin-4 Production

Concanavalin A was added to splenocytes of BALB / C mice, and the extracts prepared in Example 1 were treated, respectively, to measure the effect of inhibiting the production of interleukin-4.

Specifically, in a 96-well plate incubator containing 10% fetal bovine serum RPMI medium, mouse spleen cells were added to 400,000 cells / well, and concanavalin A was added at a concentration of 4 μg / ml. Activated. Each composition was then treated to the concentrations in Table 2 below to quantify interleukin-4 liberated into culture after 36 hours by ELISA method. At this time, using only the concanavalin A and not treated with the composition as a control group to calculate the interleukin-4 production inhibition rate according to Equation 1 shown in Table 2 the results.

Composition density(%) Interleukin-4 production inhibition rate (%) Sesin 0.001 30 Leaflets 0.001 39 device 0.001 56 riding 0.001 34 Bad news 0.001 39 Yonggyu 0.001 52 Allies 0.001 77 Ulleungchae 0.001 31 Broiler 0.001 23 Red flag 0.001 22 Small cow 0.001 24 Excess 0.001 55 Headlights 0.001 96 buckwheat 0.001 51 pigweed 0.001 28 common bistort 0.001 53 Similarity 0.001 95 Island Thyme 0.001 54 Mugwort 0.001 30 Green sprouts 0.001 50 Control - 0

As shown in Table 2, the herbal extract of the present invention was found to have the effect of inhibiting the production of interleukin-4 by activated T lymphocytes at low concentrations of 0.001%, respectively.

Test Example 3 Inhibitory Effect of T Lymphocytes on Proliferation

Concanavalin A was added to splenocytes of BALB / C mice, and the extracts prepared in Example 1 were treated, respectively, to determine the effect of inhibiting the proliferation of T lymphocytes.

Specifically, in a 96-well plate incubator containing 10% fetal bovine serum RPMI medium, spleen cells of the mouse were added to 200,000 cells / well, and Concanavalin A was added at a concentration of 2 ㎍ / ml to obtain T lymphocytes. Activated. Each composition was then incubated for 72 hours by treatment at the concentrations in Table 3 below, followed by further incubation for 12 hours by adding BrdU at a concentration of 5 μM. BrdU incorporated into proliferating T lymphocytes was quantified by ELISA method. At this time, using only the concanavalin A treatment and not treated with the composition as a control group according to the above formula 1 calculated the inhibition rate of division of T lymphocytes and the results are shown in Table 3.

Composition density(%) T lymphocyte proliferation inhibition rate (%) Sesin 0.001 20 Leaflets 0.001 20 device 0.001 68 riding 0.001 96 Bad news 0.001 50 Yonggyu 0.001 19 Allies 0.001 54 Ulleungchae 0.001 44 Broiler 0.001 54 Red flag 0.001 31 Small cow 0.001 32 Excess 0.001 32 Headlights 0.001 94 buckwheat 0.001 31 pigweed 0.001 35 common bistort 0.001 23 Similarity 0.001 90 Island Thyme 0.001 21 Mugwort 0.001 27 Green sprouts 0.001 22 Control - 0

As shown in Table 3, the herbal extracts of the present invention were found to have an effect of inhibiting the proliferation of activated T lymphocytes at low concentrations of 0.001%, respectively.

Test Example 4 Measurement of Cytotoxicity to HaCaT

HaCaT cells, which are human keratinocyte cell lines, were treated with the extract prepared in Example 1 to determine the cytotoxicity of each composition.

Specifically, HaCaT cells were dispensed at 5000 cells / well in a 96-well plate incubator containing DMEM medium containing 10% fetal calf serum and incubated for 24 hours to allow cell attachment. Each composition was incubated for 24 hours by treatment at the concentration of Table 4 below, and then 50 μl / well of tetrazolium dye was added and further cultured for 4 hours. Formazan produced by living cells was quantified by dissolving in 150 μl / well of dimethyl sulfoxide and measuring the absorbance at 570 nm. Absorbance by lysed formazan is proportional to the number of living cells. In this case, using the group not treated with the composition as a control group according to Equation 1 to calculate the inhibition rate of HaCaT cell activity is shown in Table 4 the results.

Composition density(%) HaCaT cell activity inhibition rate (%) Sesin 0.001 One Leaflets 0.001 3 device 0.001 0 riding 0.001 0 Bad news 0.001 6 Yonggyu 0.001 0 Allies 0.001 4 Ulleungchae 0.001 0 Broiler 0.001 9 Red flag 0.001 0 Small cow 0.001 0 Excess 0.001 0 Headlights 0.001 2 buckwheat 0.001 0 pigweed 0.001 9 common bistort 0.001 3 Similarity 0.001 8 Island Thyme 0.001 0 Mugwort 0.001 0 Green sprouts 0.001 4 Control - 0

Test Example 5 Cytotoxicity Measurement of Human Fibroblasts

Human fibroblasts were treated with the extract prepared in Example 1 to determine the cytotoxicity of each composition.

Specifically, fibroblasts were dispensed at 5000 cells / well in 96-well plate culture medium containing DMEM medium containing 10% fetal calf serum and incubated for 24 hours to allow cell attachment. Each composition was incubated for 24 hours by treatment at the concentration of Table 5 below, and then 50 μl / well of tetrazolium dye was added and further cultured for 4 hours. Formazan produced by living cells was quantified by dissolving in 150 μl / well of dimethylsulfoxide and measuring absorbance at 570 nm. At this time, the fibroblast activity inhibition rate was calculated according to Equation 1 using the group not treated with the composition, and the results are shown in Table 5 below.

Composition density(%) % Fibroblast Activity Inhibition Sesin 0.001 0 Leaflets 0.001 0 device 0.001 0 riding 0.001 0 Bad news 0.001 2 Yonggyu 0.001 0 Allies 0.001 2 Ulleungchae 0.001 0 Broiler 0.001 0 Red flag 0.001 0 Small cow 0.001 0 Excess 0.001 0 Headlights 0.001 0 buckwheat 0.001 0 pigweed 0.001 0 common bistort 0.001 0 Similarity 0.001 2 Island Thyme 0.001 0 Mugwort 0.001 0 Green sprouts 0.001 0 Control - 0

Test Example 6 Cytotoxicity Measurement of Mouse Spleen Cells

The splenocytes of BALB / C mice were treated with the extract prepared in Example 1 to determine the cytotoxicity of each composition.

Specifically, in a 96-well plate incubator containing RPMI medium containing 10% fetal bovine serum, spleen cells of the mice were dispensed to 500,000 cells / well, and each composition was treated according to the concentration in Table 6 below. After incubation for 50 hours, 50 μl / well of tetrazolium dye was added and further incubated for 4 hours. Formazan produced by living cells was quantified by dissolving in 150 μl / well of dimethylsulfoxide and measuring absorbance at 570 nm. At this time, the control group was treated with the composition as a control group according to the formula 1 to calculate the mouse splenocyte activity inhibition rate is shown in Table 6 the results.

Composition density(%) Inhibition rate of splenocyte activity (%) Sesin 0.001 0 Leaflets 0.001 7 device 0.001 9 riding 0.001 8 Bad news 0.001 0 Yonggyu 0.001 0 Allies 0.001 2 Ulleungchae 0.001 4 Broiler 0.001 2 Red flag 0.001 7 Small cow 0.001 One Excess 0.001 9 Headlights 0.001 0 buckwheat 0.001 0 pigweed 0.001 5 common bistort 0.001 7 Similarity 0.001 7 Island Thyme 0.001 0 Mugwort 0.001 2 Green sprouts 0.001 0 Control 0

From the results shown in Table 1, Table 2, and Table 3, it was found that the herbal extract of the present invention effectively inhibits T lymphocyte mediated immune responses such as interleukin-2, interleukin-4, and T lymphocyte division. As a result, the herbal extract of the present invention is expected to have an excellent effect in improving or preventing the symptoms of diseases such as atopic dermatitis, contact dermatitis, and psoriasis related to excessively activated T lymphocyte mediated immune responses.

In addition, as shown in Table 4, Table 5 and Table 6, the herbal extract of the present invention did not show a noticeable toxicity for human keratinocyte cell lines HaCaT cells, human fibroblasts, mouse spleen cells for 24 hours. Therefore, it can be seen that the inhibitory effect of the T lymphocyte mediated immune response by the herbal extract of the present invention is not caused by the direct toxicity of the extracts. Furthermore, these extracts are found to be very safe against keratinocytes, fibroblasts, and immune cells that are directly affected by external skin application.

<Examples 2 to 21 and Comparative Examples> Preparation of skin external preparation (cream)

In order to use the composition according to the composition of the present invention as an external preparation, a composition containing the herbal extract of Example 1 was prepared with the composition shown in Table 7 below. For comparison, a cream formulation containing no herbal extract was used as a comparative example.

Compounding Ingredients (wt%) Example 2 Example 3 Example 4 Example 5 Example 6 Example 7 Example 8 Purified water To 100 To 100 To 100 To 100 To 100 To 100 To 100 Sessin Extract 0.1 - - - - - - Leaflet extract - 0.1 - - - - - Urea extract - - 0.1 - - - - Equestrian extract - - - 0.1 - - - Royal fire extract - - - - 0.1 - - Yonggyu Extract - - - - - 0.1 - Ally extract - - - - - - 0.1 Vegetable Cured Oil 1.50 1.50 1.50 1.50 1.50 1.50 1.50 Stearic acid 0.60 0.60 0.60 0.60 0.60 0.60 0.60 Stearyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00 2.00 Glycerol Stearate 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Polyglyceryl-10 Pentastearate & Behenyl Alcohol & Sodium Stearoyl Lactylate 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Arachidil Behenyl Alcohol & Arachidil Glucoside 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Cetylaryl Alcohol & Cetearyl Glucoside 2.00 2.00 2.00 2.00 2.00 2.00 2.00 PEG-100 Stearate & Glycerolate & Propylene Glycol 1.50 1.50 1.50 1.50 1.50 1.50 1.50 Caprylic / Capric Triglycerides 11.00 11.00 11.00 11.00 11.00 11.00 11.00 Cyclomedicon 6.00 6.00 6.00 6.00 6.00 6.00 6.00 Triethanolamine 0.1 0.1 0.1 0.1 0.1 0.1 0.1

Compounding Ingredients (wt%) Example 9 Example 10 Example 11 Example 12 Example 13 Example 14 Example 15 Purified water To 100 To 100 To 100 To 100 To 100 To 100 To 100 Ulleungchae Extract 0.1 - - - - - - Broiler Extract - 0.1 - - - - - Red Bokyeongryeong Extract - - 0.1 - - - - Red Soybean Extract - - - 0.1 - - - Excess extract - - - - 0.1 - - Green Bean Extract - - - - - 0.1 - Buckwheat Extract - - - - - - 0.1 Vegetable Cured Oil 1.50 1.50 1.50 1.50 1.50 1.50 1.50 Stearic acid 0.60 0.60 0.60 0.60 0.60 0.60 0.60 Stearyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00 2.00 Glycerol Stearate 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Polyglyceryl-10 Pentastearate & Behenyl Alcohol & Sodium Stearoyl Lactylate 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Arachidil Behenyl Alcohol & Arachidil Glucoside 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Cetylaryl Alcohol & Cetearyl Glucoside 2.00 2.00 2.00 2.00 2.00 2.00 2.00 PEG-100 Stearate & Glycerolate & Propylene Glycol 1.50 1.50 1.50 1.50 1.50 1.50 1.50 Caprylic / Capric Triglycerides 11.00 11.00 11.00 11.00 11.00 11.00 11.00 Cyclomedicon 6.00 6.00 6.00 6.00 6.00 6.00 6.00 Triethanolamine 0.1 0.1 0.1 0.1 0.1 0.1 0.1

Compounding Ingredients (wt%) Example 16 Example 17 Example 18 Example 19 Example 20 Example 21 Comparative example Purified water To 100 To 100 To 100 To 100 To 100 To 100 To 100 Quinoa extract 0.1 - - - - - - Bumptail Extract - 0.1 - - - - - Cranberry Extract - - 0.1 - - - - Island Thyme Extract - - - 0.1 - - - Mugwort extract - - - - 0.1 - - Chameleon Extract - - - - - 0.1 - Vegetable Cured Oil 1.50 1.50 1.50 1.50 1.50 1.50 1.50 Stearic acid 0.60 0.60 0.60 0.60 0.60 0.60 0.60 Stearyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00 2.00 Glycerol Stearate 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Polyglyceryl-10 Pentastearate & Behenyl Alcohol & Sodium Stearoyl Lactylate 1.00 1.00 1.00 1.00 1.00 1.00 -1.00 Arachidil Behenyl Alcohol & Arachidil Glucoside 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Cetylaryl Alcohol & Cetearyl Glucoside 2.00 2.00 2.00 2.00 2.00 2.00 2.00 PEG-100 Stearate & Glycerolate & Propylene Glycol 1.50 1.50 1.50 1.50 1.50 1.50 1.50 Caprylic / Capric Triglycerides 11.00 11.00 11.00 11.00 11.00 11.00 11.00 Cyclomedicon 6.00 6.00 6.00 6.00 6.00 6.00 6.00 Triethanolamine 0.1 0.1 0.1 0.1 0.1 0.1 0.1

Test Example 7 Atopic Symptom Improvement Test in Human Body

In order to confirm the effect of improving atopic symptoms by the composition of the present invention, the creams prepared in Comparative Examples and Examples 4 (element), 5 (equestrian), 8 (friend) and 14 (cephalosphere) were applied to the panels. The degree of atopic dermatitis improvement was evaluated.

For 50 panelists who thought there were symptoms of dermatitis showing similar symptoms, each group of 10 persons was divided into 5 groups, and each composition of Table 7 was twice daily for 12 weeks at a temperature of 24 to 26 ° C and a humidity of 75% for 12 weeks. It was applied to the face. At the end of the study, subjects were asked to complete a questionnaire and subjective efficacy evaluations were conducted. The questionnaire included symptoms of atopic dermatitis such as “pruritus”, “dryness”, “keratogenesis”, “dandruff”, “erythema”, “swelling”, “skin cracking”, “truth and eczema”, and “chorus” In the case of the above symptoms, the degree of improvement for each symptom was evaluated and averaged to evaluate the effect of improving atopy symptoms for each individual. The results are shown in Table 8.

Applicator Respondents (Personal) Markedly improved Improving No change worse Comparative example One 3 6 0 Example 4 (element) 5 4 One 0 Example 5 (Riding) 5 4 One 0 Example 8 (friend) 5 4 One 0 Example 14 (super head) 4 5 One 0

From Table 8, it was confirmed that atopic dermatitis symptoms improved when the composition containing the herbal extract of the present invention was applied. In any case, there was no hypersensitivity reaction or side effects caused by the composition.

Claims (2)

A skin external preparation composition for treating or preventing atopic dermatitis, contact dermatitis or psoriasis, which contains a pan-tail extract as an active ingredient. The composition for external application for skin according to claim 1, wherein the Bumtail extract is contained in an amount of 0.001 to 10% by weight based on the total weight of the composition.